Identification of a 3-hydroxylated tacrine metabolite in rat and man: Metabolic profiling implications and pharmacology

Journal of Medicinal Chemistry

Volumn 39, Issue 15, 1996, Pages 3014-3018

  Pool, William F ^a   Woolf, Thomas F ^a   Reily, Michael D ^a   Caprathe, Bradley W ^a   Emmerling, Mark R ^a   Jaen, Juan C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYTACRINE; 4 HYDROXYTACRINE; ACETYLCHOLINESTERASE; CARBON 14; CHOLINESTERASE INHIBITOR; DRUG METABOLITE; TACRINE; TACRINE DERIVATIVE; UNCLASSIFIED DRUG; VELNACRINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; CHOLINERGIC SYSTEM; CHOLINESTERASE INHIBITION; DRUG METABOLISM; ENZYME ASSAY; ERYTHROCYTE; GASTROINTESTINAL SYMPTOM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIVER TOXICITY; MALE; MASS SPECTROMETRY; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; URINARY EXCRETION;

ACETYLCHOLINESTERASE; ANIMALS; CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ERYTHROCYTES; HUMANS; HYDROXYLATION; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MOLECULAR STRUCTURE; RATS; TACRINE;

EID: 0030008423     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9602266     Document Type: Article

References (18)

1. Knapp, M. J.; Knopman, D. S.; Soloman, P. R.; Pendlebury, W, W.; Davis, C. S.; Gracon, S. I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. J. Am. Med. Assoc. 1994, 271 985-991.
2. Crismon, M. L. Tacrine: first drug approved for Alzheimer's disease. Ann. Pharmacother. 1994, 28, 744-751.
3. Nordberg, A. Biological markers and the cholinergic hypothesis in Alzheimer's disease. Acta Neurol. Scand. 1992, Suppl. 85, 54-58.
4. Hakansson, L. Mechanism of action of cholinesterase inhibitors in Alzheimer's disease. Acta Neruol. Scand. 1993, Suppl. 88, 7-9.
5. Watkins, P. B.; Zimmerman, H. J.; Knapp, M. J.; Gracon, S. I.; Lewis, K. W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. J. Am. Med. Assoc. 1994, 271, 992-998.
6. Gracon, S. I.; Hoover, T. M.; Lewis, K. W.; Dolan-Ureno, J.; Rieger, M. M.; Mers, S. L.; Knapp, M. J. Tacrine in Alzheimer's disease: efficacy and safety in a parallel-group study. In Alzheimer's disease: advances in clinical and basic research; Corain, B., Iqbal, K., Nicolini, M., Winblad, B., Wisniewski, H., Zatta, P., Eds.; Wiley: New York, 1993; pp 551-557.
7. Ames, D. J.; Bhathal, P. S.; Davies, B. M.; Fraser, J. R. E.; Gibson, P. R.; Roberts, S. Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine. Aust. NZ J. Med. 1990, 20, 193-195.
8. Madden, S.; Spaldin, V.; Park, B. K. Clinical pharmacokinetics of tacrine. Clin. Pharmacokinet. 1995, 28, 449-457.
9. Pool, W. F.; Bjorge, S. M.; Chang, T.; Woolf, T. F. Effect of 3-methylcholanthrene induction on the disposition of the cognition activator tacrine in rat. ISSX Proceedings, Fourth North American ISSX Meeting, 1992; p 163.
10. Pool, W. F.; Bjorge, S. M.; Chang, T.; Woolf, T. F. Metabolic disposition of the cognition activator tacrine in man: identification of phenol glucuronide metabolites in urine, ISSX Proceedings, Fourth North American ISSX Meeting, 1992; p 164.
11. Pool, W. F.; Bjorge, S. M.; Reily, M. D.; Chang, T.; Woolf, T. F. Metabolic disposition of the cognition activator tacrine in dog: identification of dihydroxy metabolites including a dihydrodiol. ISSX Proceedings, Fourth North American ISSX Meeting, 1992; p 162.
12. Hsu, R. S.; Shutske, G. M.; Dileo, E. M.; Chesson, S. M.; Linville, A. R.; Allen, R. C. Identification of the urinary metabolites of tacrine in the rat. Drug Metab. Dispos. 1990, 18, 779-783.
13. Shutske, G. M.; Bores, G. M.; Bradshaw, K. C.; Huger, F. P.; Kapples, K. J.; Larsen, R. D.; Rush, D. K.; Tomer, J. D. Synthesis and biological activity of putative mono-hydroxylated metabolites of velnacrine. Bioorg. Med. Chem. Lett. 1992, 2, 865-70.
14. Oliver, J. E.; Waters, R. M.; Lusby, W. R. Synthesis of 2-do-decanoyl-3,5-dihydroxy-2-cyclohexen-1-one. Tetrahedron 1990, 46, 1125-1130.
15. Lau, C. K.; Tardiff, S.; Dufresne, C.; Scheigetz, J. Reductive deoxygenation of aryl aldehydes and ketones by tert-butylamineborane and aluminum chloride. J. Org. Chem. 1989, 54, 491-494.
16. Ashour, M.-B, A.; Gee, S. J.; Hammock, B. D. Use of a 96-well microplate reader for measuring enzyme activities. Anal. Biochem. 1987, 166, 353-360.
17. McNally, W. P.; Pool, W. F.; Sinz, M. W.; DeHart, P.; Ortwine, D. F.; Huang, C. C.; Chang, T.; Woolf, T. F. Distribution of tacrine and metabolites in rat brain and plasma following single and multiple dose regimens: evidence for accumulation of tacrine in rat brain tissue. Drug Metab. Dispos. 1996, 24, 628-633.
18. Bax, A.; Freeman, R. Investigation of complex networks of spin-spin coupling by two-dimensional NMR. J. Magn. Reson. 1981, 44, 542-561.